ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0080

COVID-19 and CKD: An Overview of Reviews to Inform the World Health Organization Scientific Brief

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Jdiaa, Sara Saleh, University of Toronto, Toronto, Ontario, Canada
  • Mansour, Razan, The University of Kansas Health System, Kansas City, Kansas, United States
  • Alayli, Abdallah El, The University of Kansas Health System, Kansas City, Kansas, United States
  • Gautam, Archana, The University of Kansas Health System, Kansas City, Kansas, United States
  • Thomas, Preston J., The University of Kansas Health System, Kansas City, Kansas, United States
  • Mustafa, Reem, The University of Kansas Health System, Kansas City, Kansas, United States
Background

The World Health organization (WHO) declared COVID-19 as a global pandemic in March of 2020. Many studies have assessed the association between different comorbidities and COVID-19 outcomes. In this overview of reviews, we aim to summarize the association between CKD and different COVID-19 outcomes.

Methods

We performed a systematic search through Embase, PubMed, Epistemonikos, and Cochrane as well as preprint databases from January 1, 2020 to January 5, 2021. After searching systematic reviews, we updated the search by identifying primary studies published after August 2020, which was the date of last search in the reviews. We focused on systematic reviews and large primary studies. We followed the GRADE methodology to assess the certainty in effect estimates. Data was pooled based on random effects model.

Results

We included a total of 69 systematic reviews and 66 primary studies in our overview. We did not identify any systematic reviews that directly reports on CKD and the risk of contracting COVID-19. There was no convincing difference on the risk of acquiring COVID-19 infection in patients with and without CKD in primary studies (OR = 1.00, 95% CI 0.76-1.33). CKD is associated with higher risk of COVID-19 related mortality pooled hazard ratio (HR) 1.48 (95% CI 1.33-1.65) and pooled odds ratio (OR) 1.77 (95% CI 1.54-2.02)(moderate certainty), hospitalization pooled risk ratio (RR) 1.63 (95% CI 1.03-2.58) (moderate certainty) and disease severity pooled RR 1.56 (95% CI 1.3-1.86) (moderate certainty). Notably, the risk of COVID-19 attributed hospitalization and mortality were higher in patients with more advanced CKD stage.

Conclusion

Evidence consistently demonstrated an increased risk of mortality, hospitalization and disease severity in patients with CKD and COVID-19 infection. The results highlight the importance of recognizing patients with CKD as a high-risk group and of prioritizing these patients for COVID-19 prevention strategies including vaccination.